Hodgkin Lymphoma
Conference Coverage
Variations in blood cancer survival across Europe
chemotherapy Photo by Rhoda Baer VIENNA—Results of the EUROCARE-5 study have revealed regional differences in survival for European patients with...
News
First-line BV can produce high response rate in older HL patients
Photo from Business Wire First-line treatment with brentuximab vedotin (BV) can produce a high response rate in older Hodgkin lymphoma (HL)...
News
Blood cancer drugs set to be removed from CDF
Photo courtesy of CDC England’s National Health Service (NHS) plans to remove several drugs used to treat hematologic malignancies from the...
News
FDA approves brentuximab vedotin as consolidation
Photo from Business Wire The US Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) for use as consolidation treatment...
Conference Coverage
Interim PET results guide ongoing therapy in Hodgkin lymphoma
Key clinical point: Bleomycin can be eliminated after two cycles of the ABVD chemotherapeutic regimen based on a negative interim PET scan finding...
Conference Coverage
Novel mAb targeting CD70 shows activity in TCL
Photo by Linda Bartlett LUGANO—The defucosylated monoclonal antibody (mAb) ARGX-110, which is active against CD70-bearing tumor cells and CD70-...
Conference Coverage
Team endorses intensified chemo for PET-positive HL
Photo by Rhoda Baer LUGANO—Long-awaited results of the Intergroup H10 trial in PET-positive Hodgkin lymphoma (HL) patients have shown that...
Conference Coverage
‘Radically different’ PI3Kδ inhibitor lacks hepatotoxicity
Photo by Larry Young LUGANO—Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated...
Conference Coverage
Nivolumab produces ‘dramatic’ responses in HL
Photo courtesy of UCLA LUGANO—The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in...
Conference Coverage
Bleomycin can be safely omitted after negative PET2 in HL
Photo by Jens Maus LUGANO—Results of the RATHL trial indicate that bleomycin can be omitted from ABVD therapy following a negative interim FDG-...
News
Alisertib shows activity in non-Hodgkin lymphoma
Key clinical point: Alisertib has shown significant antitumor activity in patients with relapsed or refractory peripheral T-cell non-Hodgkin...